Kymera Therapeutics Future Growth
Future criteria checks 0/6
Kymera Therapeutics's revenue and earnings are forecast to decline at 2.5% and 10.6% per annum respectively. EPS is expected to decline by 5.3% per annum. Return on equity is forecast to be -103.9% in 3 years.
Key information
-10.6%
Earnings growth rate
-5.35%
EPS growth rate
| Biotechs earnings growth | 24.3% |
| Revenue growth rate | -2.5% |
| Future return on equity | -103.93% |
| Analyst coverage | Good |
| Last updated | 30 Nov 2025 |
Recent future growth updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates
Aug 14
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 01Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Recent updates
Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum
Dec 08Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates
Aug 14Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week
May 13Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
May 08
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings.Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 01Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line
Feb 19Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely
Feb 17Kymera: Protein Degradation Could Drive Dupixent-Like Value
Dec 07Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 45 | -384 | -304 | -273 | 18 |
| 12/31/2026 | 47 | -338 | -295 | -274 | 22 |
| 12/31/2025 | 53 | -296 | -245 | -214 | 22 |
| 9/30/2025 | 44 | -295 | -230 | -228 | N/A |
| 6/30/2025 | 45 | -275 | -253 | -251 | N/A |
| 3/31/2025 | 59 | -241 | -240 | -234 | N/A |
| 12/31/2024 | 47 | -224 | -207 | -195 | N/A |
| 9/30/2024 | 88 | -167 | -148 | -125 | N/A |
| 6/30/2024 | 89 | -158 | -138 | -106 | N/A |
| 3/31/2024 | 79 | -155 | -136 | -98 | N/A |
| 12/31/2023 | 79 | -147 | -137 | -103 | N/A |
| 9/30/2023 | 47 | -167 | -174 | -150 | N/A |
| 6/30/2023 | 52 | -158 | -169 | -153 | N/A |
| 3/31/2023 | 47 | -159 | -163 | -157 | N/A |
| 12/31/2022 | 47 | -155 | -156 | -153 | N/A |
| 9/30/2022 | 46 | -154 | -155 | -152 | N/A |
| 6/30/2022 | 57 | -139 | -157 | -155 | N/A |
| 3/31/2022 | 64 | -124 | -148 | -146 | N/A |
| 12/31/2021 | 73 | -100 | -131 | -129 | N/A |
| 9/30/2021 | 70 | -79 | -113 | -111 | N/A |
| 6/30/2021 | 65 | -58 | 54 | 58 | N/A |
| 3/31/2021 | 49 | -48 | 69 | 77 | N/A |
| 12/31/2020 | 34 | -55 | 79 | 88 | N/A |
| 9/30/2020 | 23 | -53 | 90 | 97 | N/A |
| 6/30/2020 | 9 | -57 | -52 | -47 | N/A |
| 3/31/2020 | 6 | -52 | -17 | -15 | N/A |
| 12/31/2019 | 3 | -41 | 17 | 18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KYMR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KYMR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KYMR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KYMR's revenue is expected to decline over the next 3 years (-2.5% per year).
High Growth Revenue: KYMR's revenue is forecast to decline over the next 3 years (-2.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KYMR is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 18:23 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kymera Therapeutics, Inc. is covered by 36 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |